FOUNDED

EBBU, SEED TO $330M CANOPY GROWTH ACQUISITION

ANTHARIS THERAPEUTICS RECAPITALIZATION

MYDX, SEED TO PUBLIC COMPANY

Primary Industries of Investment

Portfolio Companies Featured In

Our Team

Daniel Yazbeck, M.Sc.
Founder and CEO

Former  Pfizer  scientist. Panasonic business builder. Global CEO. Daniel Yazbeck has spent his career turning science and technology into profitable businesses. He founded Yazbeck & Co. in 2008, backed companies through exits including MyDx and Ebbu, and today leads the firm’s healthcare and technology investments. Featured in Bloomberg, CNN, VICE News, Fast Company, ABC, NBC, PBS, and CNET.

Jason Laba, Senior Managing Director

Lawyer by training. Dealmaker by trade. Jason Laba leads Yazbeck & Co.’s agriculture investments and has advised on transactions across Canada, the United States, and internationally. He previously worked for the Legislative Assembly of Ontario and served as CEO of Natural Stems, a medical cannabis company.

Active Investments

Antharis Therapeutics

Antharis Therapeutics is developing next-generation antibody-drug conjugates (ADCs) for cancer.

Read More →

Elemental Biologics

Advancing Antibody Therapeutics for Inflammatory and Immune-Driven Diseases.

Read More →

Tillat Pharmaceuticals

Tillat is building a trusted global brand of medicines for a large, underserved patient population.

Read More →

In The News

Lonza Issues Exclusive, Target-Specific License to Antharis Therapeutics to Advance Next-Generation Dual Payload ADCs for Gastrointestinal Cancers…

Read More →

Bloomberg Canada Features Daniel Yazbeck
…

Read More →